Over the past 12 months, 3 insiders at NEKTAR THERAPEUTICS filed 31 open-market SEC Form 4 transactions on NKTR: 0 purchases worth $0 and 31 sales worth $3.0M. Insiders have been net sellers over this period. The most recent filing was on Jun 30, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 30, 26 | Jonathan ZalevskyChief R&D Officer | SELL | 5.7K | $70.00 | $398K |
| Jun 17, 26 | Howard W RobinPresident & CEO | SELL | 5.5K | $61.65 | $334K |
| Jun 16, 26 | Howard W RobinPresident & CEO | SELL | 5.3K | $60.71 | $318K |
| Feb 18, 26 | Howard W RobinPresident & CEO | SELL | 423 | $73.00 | $31K |
| Feb 18, 26 | Jonathan ZalevskyChief R&D Officer | SELL | 180 | $73.00 | $13K |
| Jan 20, 26 | Jonathan ZalevskyChief R&D Officer | SELL | 3.9K | $35.67 | $138K |
| Nov 25, 25 | Howard W RobinPresident & CEO | SELL | 2.2K | $54.28 | $120K |
| Nov 25, 25 | Mark Andrew WilsonChief Legal Officer | SELL | 630 | $54.28 | $34K |
| Nov 25, 25 | Jonathan ZalevskyChief R&D Officer | SELL | 1.2K | $54.28 | $63K |
| Sep 9, 25 | Howard W RobinPresident & CEO | SELL | 2.2K | $48.18 | $102K |
| Sep 5, 25 | Howard W RobinPresident & CEO | SELL | 3.3K | $39.89 | $125K |
| Sep 4, 25 | Howard W RobinPresident & CEO | SELL | 1.9K | $35.80 | $62K |
| Sep 4, 25 | Jonathan ZalevskyChief R&D Officer | SELL | 793 | $35.69 | $26K |
| Sep 2, 25 | Howard W RobinPresident & CEO | SELL | 1.5K | $30.16 | $45K |
| Sep 2, 25 | Jonathan ZalevskyChief R&D Officer | SELL | 485 | $30.10 | $15K |
| Aug 19, 25 | Howard W RobinPresident & CEO | SELL | 1.6K | $26.59 | $42K |
| Aug 19, 25 | Mark Andrew WilsonChief Legal Officer | SELL | 676 | $26.59 | $18K |
| Aug 19, 25 | Jonathan ZalevskyChief R&D Officer | SELL | 725 | $26.59 | $19K |
| May 19, 25 | Howard W RobinPresident & CEO | SELL | 23.2K | $0.67 | $16K |
| May 19, 25 | Mark Andrew WilsonChief Legal Officer | SELL | 10.0K | $0.67 | $7K |
| May 19, 25 | Jonathan ZalevskyChief R&D Officer | SELL | 10.7K | $0.67 | $7K |
| Feb 19, 25 | Howard W RobinPresident & CEO | SELL | 23.8K | $1.01 | $24K |
| Feb 19, 25 | Mark Andrew WilsonChief Legal Officer | SELL | 11.0K | $1.01 | $11K |
| Feb 19, 25 | Jonathan ZalevskyChief R&D Officer | SELL | 10.3K | $1.01 | $10K |
| Dec 24, 24 | Mark Andrew WilsonChief Legal Officer | SELL | 16.6K | $0.89 | $15K |
| Dec 23, 24 | Mark Andrew WilsonChief Legal Officer | SELL | 33.4K | $0.90 | $30K |
| Dec 19, 24 | Jonathan ZalevskyChief R&D Officer | SELL | 51.1K | $0.94 | $48K |
| Dec 18, 24 | Howard W RobinPresident & CEO | SELL | 85.0K | $0.99 | $84K |
| Dec 17, 24 | Howard W RobinPresident & CEO | SELL | 47.0K | $1.01 | $47K |
| Nov 19, 24 | Howard W RobinPresident & CEO | SELL | 16.3K | $1.01 | $16K |
| Nov 19, 24 | Mark Andrew WilsonChief Legal Officer | SELL | 6.4K | $1.01 | $6K |
| Nov 19, 24 | Jonathan ZalevskyChief R&D Officer | SELL | 7.8K | $1.01 | $8K |
| Aug 19, 24 | Howard W RobinPresident & CEO | SELL | 14.9K | $1.28 | $19K |
| Aug 19, 24 | Mark Andrew WilsonChief Legal Officer | SELL | 5.7K | $1.28 | $7K |
| Aug 19, 24 | Jonathan ZalevskyChief R&D Officer | SELL | 6.9K | $1.28 | $9K |
| Jun 14, 24 | Robert ChessDirector | SELL | 19.5K | $1.20 | $23K |
| May 17, 24 | Howard W RobinPresident & CEO | SELL | 16.6K | $1.75 | $29K |
| May 17, 24 | Mark Andrew WilsonChief Legal Officer | SELL | 6.3K | $1.75 | $11K |
| May 17, 24 | Jonathan ZalevskyChief R&D Officer | SELL | 7.4K | $1.75 | $13K |
| May 10, 24 | David KroinTenPercentOwner | SELL | 56.0K | $1.78 | $100K |
| Feb 20, 24 | Howard W RobinPresident & CEO | SELL | 20.0K | $0.68 | $14K |
| Feb 20, 24 | Mark Andrew WilsonChief Legal Officer | SELL | 7.6K | $0.68 | $5K |
| Feb 20, 24 | Jonathan ZalevskyChief R&D Officer | SELL | 9.0K | $0.68 | $6K |
| Nov 17, 23 | Howard W RobinPresident & CEO | SELL | 19.9K | $0.49 | $10K |
| Nov 17, 23 | Mark Andrew WilsonChief Legal Officer | SELL | 7.2K | $0.49 | $4K |
| Nov 17, 23 | Jonathan ZalevskyChief R&D Officer | SELL | 9.6K | $0.49 | $5K |
| Sep 18, 23 | Jeffrey Robert AjerDirector | SELL | 4.4K | $0.69 | $3K |
| Sep 18, 23 | Myriam CuretDirector | SELL | 4.4K | $0.69 | $3K |
| Aug 16, 23 | Howard W RobinPresident & CEO | SELL | 20.0K | $0.78 | $16K |
| Aug 16, 23 | Mark Andrew WilsonChief Legal Officer | SELL | 7.2K | $0.78 | $6K |
Over the past 12 months, insiders at NEKTAR THERAPEUTICS filed 0 open-market purchases worth $0 and 31 sales worth $3.0M on NKTR, which makes them net sellers over the period. The most recent Form 4 was filed on Jun 30, 26.
3 different insiders at NEKTAR THERAPEUTICS filed open-market SEC Form 4 transactions on NKTR over the last 12 months.
InsiderTape plots every NKTR insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every NEKTAR THERAPEUTICS insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →